Citigroup’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-1,770,806
| Closed | -$31.9M | – | 7765 |
|
|
2020
Q2 | $31.9M | Buy |
1,770,806
+1,684,734
| +1,957% | +$23.4M | 0.02% | 578 |
|
|
2020
Q1 | $614K | Buy |
86,072
+21,501
| +33% | +$268K | ﹤0.01% | 3677 |
|
|
2019
Q4 | $1.54M | Sell |
64,571
-60,484
| -48% | -$1.67M | ﹤0.01% | 3282 |
|
|
2019
Q3 | $3.35M | Sell |
125,055
-99,343
| -44% | -$2.79M | ﹤0.01% | 2309 |
|
|
2019
Q2 | $6.09M | Buy |
224,398
+201,501
| +880% | +$6.32M | ﹤0.01% | 1809 |
|
|
2019
Q1 | $794K | Sell |
22,897
-552,248
| -96% | -$15.9M | ﹤0.01% | 3665 |
|
|
2018
Q4 | $11.2M | Buy |
575,145
+36,649
| +7% | +$754K | 0.01% | 1179 |
|
|
2018
Q3 | $14.3M | Buy |
538,496
+449,005
| +502% | +$14.7M | 0.01% | 1050 |
|
|
2018
Q2 | $3.38M | Buy |
89,491
+11,607
| +15% | +$444K | ﹤0.01% | 2202 |
|
|
2018
Q1 | $2.54M | Sell |
77,884
-3,178
| -4% | -$139K | ﹤0.01% | 2386 |
|
|
2017
Q4 | $3.95M | Buy |
81,062
+21,048
| +35% | +$1.06M | ﹤0.01% | 2064 |
|
|
2017
Q3 | $3.24M | Buy |
60,014
+6,800
| +13% | +$399K | ﹤0.01% | 2159 |
|
|
2017
Q2 | $2.99M | Buy |
53,214
+21,347
| +67% | +$855K | ﹤0.01% | 2163 |
|
|
2017
Q1 | $1.25M | Sell |
31,867
-107,221
| -77% | -$3.41M | ﹤0.01% | 2982 |
|
|
2016
Q4 | $3.12M | Buy |
139,088
+135,920
| +4,290% | +$2.66M | ﹤0.01% | 2393 |
|
|
2016
Q3 | $72K | Sell |
3,168
-648
| -17% | -$15.2K | ﹤0.01% | 5422 |
|
|
2016
Q2 | $90K | Sell |
3,816
-71,147
| -95% | -$1.76M | ﹤0.01% | 5162 |
|
|
2016
Q1 | $1.53M | Sell |
74,963
-730,473
| -91% | -$23.2M | ﹤0.01% | 2830 |
|
|
2015
Q4 | $41.4M | Buy |
805,436
+204,715
| +34% | +$9.93M | 0.04% | 427 |
|
|
2015
Q3 | $25.6M | Buy |
600,721
+592,160
| +6,917% | +$28.6M | 0.02% | 601 |
|
|
2015
Q2 | $389K | Sell |
8,561
-3,350
| -28% | -$135K | ﹤0.01% | 3939 |
|
|
2015
Q1 | $452K | Sell |
11,911
-5,589
| -32% | -$192K | ﹤0.01% | 3838 |
|
|
2014
Q4 | $496K | Buy |
17,500
+16,216
| +1,263% | +$451K | ﹤0.01% | 3894 |
|
|
2014
Q3 | $32K | Sell |
1,284
-1,489
| -54% | -$39.2K | ﹤0.01% | 5605 |
|
|
2014
Q2 | $81K | Sell |
2,773
-1,982
| -42% | -$48K | ﹤0.01% | 4829 |
|
|
2014
Q1 | $124K | Sell |
4,755
-1,794
| -27% | -$47.9K | ﹤0.01% | 4786 |
|
|
2013
Q4 | $168K | Buy |
6,549
+6,534
| +43,560% | +$159K | ﹤0.01% | 4810 |
|
|
2013
Q3 | $0 | Sell |
15
-4,497
| -100% | -$107K | ﹤0.01% | 7077 |
|
|
2013
Q2 | $111K | Buy |
+4,512
| New | +$89.7K | ﹤0.01% | 4767 |
|
Citigroup's PTLA Position: Q3 2020 in Review
Citigroup sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 1,770,806 shares — an estimated $31.9M sold.
Citigroup first reported a position in PTLA in Q2 2013 and held it in 29 quarters. The position peaked at $41.4M in Q4 2015. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Citigroup reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Citigroup sold 1,770,806 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $31.9M.
- Citigroup first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- Citigroup's Portola Pharmaceuticals, Inc. position peaked at $41.4M in Q4 2015.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Citigroup's 13F filing for Q3 2020, filed 12 Nov 2020.